Fibroblast growth factor 23-Klotho: A new axis of phophate balance control;Le facteur de croissance des fibroblastes 23 et son récepteur Klotho: Un nouvel axe de régulation du bilan du phosphate

Medecine/Sciences

Volumn 25, Issue 5, 2009, Pages 489-495

  Prié, Dominique ^a,b   Torres, Pablo Ureña ^c   Friedlander, Gérard ^b,d  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b INSERM   (France)

^c Clinique du Landy   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; PHOSPHATE; SECRETED FRIZZLED RELATED PROTEIN 4;

ABSORPTION; BLOOD VESSEL CALCIFICATION; BONE MINERALIZATION; CELL PROLIFERATION; GENETIC DISORDER; HUMAN; KIDNEY; KIDNEY PROXIMAL TUBULE; LIFESPAN; METABOLISM; NONHUMAN; PHOSPHATE BALANCE; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVIEW; SENESCENCE; SOFT TISSUE CALCIFICATION;

ANIMALIA;

EID: 66849093715     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2009255489     Document Type: Review

References (39)

1. Prie D, Beck L, Urena P, Friedlander G. Recent findings in phosphate homeostasis. Curr Opin Nephrol Hypertens 2005 ; 14 : 318-324 (Pubitemid 40863067)
2. Mirams M, Robinson BG, Mason RS, Nelson AE. Bone as a source of FGF23: regulation by phosphate? Bone 2004 ; 35 : 1192-1199
3. ADHR c. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000 ; 26 : 345-348
4. Prie D, Urena P, Friedlander G. Latest findings in phosphate homeostasis. Kidney Int 2009 ; 4 février online.
5. Ward LM, Rauch F, White KE, et al. Resolution of severe, adolescent-onset hypophosphatemic rickets following resection of an FGF-23-producing tumour of the distal ulna. Bone 2004 ; 34 : 905-911 (Pubitemid 38581137)
6. Yamazaki Y, Okazaki R, Shibata M, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002 ; 87 : 4957-4960 (Pubitemid 35316332)
7. Burnett SM, Gunawardene SC, Bringhurst FR, et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006 ; 21 : 1187-1196 (Pubitemid 44128331)
8. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005 ; 90 : 1519-1524 (Pubitemid 40464013)
9. Nishi H, Nii-Kono T, Nakanishi S, et al. Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 2005 ; 101 : c94-9. (Pubitemid 41208897)
10. Liu S, Tang W, Zhou J, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006 ; 17 : 1305-1315 (Pubitemid 43673410)
11. Kolek OI, Hines ER, Jones MD, et al. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 2005 ; 289 : G1036-42. (Pubitemid 41740608)
12. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005 ; 16 : 2205-2215 (Pubitemid 41716454)
13. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003 ; 64 : 2272-2279 (Pubitemid 37449564)
14. Urena Torres P, Friedlander G, de Vernejoul MC, Silve C, Prie D. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int 2008 ; 73 : 102-107 (Pubitemid 350273643)
15. Shimada T, Urakawa I, Yamazaki Y, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004 ; 314 : 409-414 (Pubitemid 38084732)
16. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001 ; 98 : 6500-6505 (Pubitemid 32488266)
17. Saito H, Kusano K, Kinosaki M, et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem 2003 ; 278 : 2206-2211 (Pubitemid 36801287)
18. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007 ; 117 : 4003-4008 (Pubitemid 350224109)
19. Krajisnik T, Bjorklund P, Marsell R, et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007 ; 195 : 125-131 (Pubitemid 350056006)
20. Shimada T, Muto T, Urakawa I, et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002 ; 143 : 3179-3182 (Pubitemid 34809892)
21. Razzaque MS, Sitara D, Taguchi T, St-Arnaud R, Lanske B. Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. Faseb J 2006 ; 20 : 720-722 (Pubitemid 46671193)
22. Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004 ; 113 : 561-568 (Pubitemid 38542505)
23. Stubbs JR, Liu S, Tang W, et al. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 2007 ; 18 : 2116-2124 (Pubitemid 47041077)
24. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997 ; 390 : 45-51. (Pubitemid 27494749)
25. Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003 ; 17 : 2393-2403 (Pubitemid 37542205)
26. Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006 ; 281 : 6120-6123 (Pubitemid 43847540)
27. Urokawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006 ; 444 : 770-774
28. White KE, Cabral JM, Davis SI, et al. Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet 2005 ; 76 : 361-367 (Pubitemid 40129563)
29. Liu S, Vierthaler L, Tang W, Zhou J, Quarles LD. FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol 2008 ; 19 : 2342-2350
30. Chang Q, Hoefs S, van der Kemp AW, et al. The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 2005 ; 310 : 490-493
31. Kurosu H, Yamamoto M, Clark JD, et al. Suppression of aging in mice by the hormone Klotho. Science 2005 ; 309 : 1829-1833 (Pubitemid 41325087)
32. Yamamoto M, Clark JD, Pastor JV, et al. Regulation of oxidative stress by the anti-aging hormone klotho. J Biol Chem 2005 ; 280 : 38029-38034 (Pubitemid 41642417)
33. Koh N, Fujimori T, Nishiguchi S, et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 2001 ; 280 : 1015-1020 (Pubitemid 32924441)
34. Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007 ; 18 : 2600-2608 (Pubitemid 47378877)
35. Kazama JJ, Sato F, Omori K, et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 2005 ; 67 : 1120-1125 (Pubitemid 41623338)
36. Nakanishi S, Kazama JJ, Nii-Kono T, et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005 ; 67 : 1171-1178 (Pubitemid 41623344)
37. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008 ; 359 : 584-592
38. Evenepoel P, Naesens M, Claes K, Kuypers D, Vanrenterghem Y. Tertiary hyperphosphatoninism accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 2007 ; 7 : 1193-1200 (Pubitemid 46643105)
39. Haruna Y, Kashihara N, Satoh M, et al. Amelioration of progressive renal injury by genetic manipulation of Klotho gene. Proc Natl Acad Sci USA 2007 ; 104 : 2331-2336 (Pubitemid 46391397)